Cytonics, Inc. is a biotechnology company focused on developing innovative diagnostics and therapeutics for osteoarthritis (OA). Their flagship product, the Fibronectin-Aggrecan Complex Test (FACT™), is a diagnostic tool that detects cartilage damage in patients through joint fluid samples. This test has been widely adopted by physicians to guide treatment decisions. Additionally, Cytonics has developed the Autologous Platelet Integrated Concentration (APIC™) system, which utilizes a patient's own blood to concentrate alpha-2-macroglobulin (A2M), a naturally occurring protein that protects cartilage from degradation. This therapy has shown promising results in alleviating joint pain and has been administered to over 6,000 patients since its introduction.

The company is also advancing a recombinant version of A2M, known as CYT-108, which aims to provide a more effective treatment option for OA. This synthetic drug is designed to function more efficiently than naturally occurring A2M and has demonstrated potential in preclinical studies to slow the progression of osteoarthritis. Cytonics' commitment to research and development is underscored by their extensive patent portfolio and collaborations with leading research institutions. Their mission is to improve the quality of life for individuals suffering from osteoarthritis through cutting-edge regenerative medicine technologies.

United States

Cytonics is a research and development company dedicated to discovering and developing therapeutics based on the protease inhibitor Alpha2 Macroglobulin (A2M). Theyhave discovered a unique “bio-marker” that can assist physicians in improving patient outcomes by pinpointing the source of orthopedic pain. We are also developing a range of therapeutic products for the treatment of painful osteoarthritis, back, and joint pain.

Cytonics, Inc.

Company Details